FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Global approvals · expansion Has completed a Phase 3 trial in Japan for CARTISTEM, already used in Korea, and started dosing in a US Phase 3 trial.

  • Announced first patient dosing in the US Phase 3 trial of CARTISTEM. Source
  • Announced that the Japanese Phase 3 trial of CARTISTEM met its primary endpoints. Source

Roles often seen at this stageClinical & PV · Regulatory affairs · Manufacturing & MSAT

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Medipost

A biotech company behind the cord-blood-derived stem cell therapy CARTISTEM and the Celltree cord blood bank, which has stored samples for more than 340,000 people.

CARTISTEM

Marketed

An allogeneic cord-blood-derived stem cell therapy for cartilage regeneration in knee osteoarthritis, with real-world data from about 560 patients in Korea.

CARTISTEM Japan Phase 3

Phase 3

A Phase 3 trial in 130 patients at 13 Japanese sites met its primary endpoints; Teikoku Pharma holds exclusive distribution rights in Japan.

CARTISTEM US Phase 3

Phase 3

A single pivotal Phase 3 trial in 300 patients at about 70 sites in the US and Canada, with first dosing in July 2026.

Celltree

Service

Cord blood bank with more than 340,000 people stored; the company has also begun storing umbilical cord tissue, fat and immune cells.

Completion reported

Enrolled and dosed the first patient in the US Phase 3 trial of CARTISTEM.

Completion reported

Announced that the Japanese Phase 3 trial of CARTISTEM met its primary endpoints.

Completion reported

Launched storage services for umbilical cord tissue, fat and immune cells.

Official role guide

Medipost careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page was found, but postings and duties were not read in this check.
Experience & requirements
Unconfirmed — Requirements were not checked on the official careers page.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 2026년 상반기 별도 매출 413억 원 달성… 영업이익 흑자기조 지속 ↗메디포스트 · Published 2026-08-14 · Sources checked 2026-11-18 · Original unavailable
  2. 메디포스트, '카티스템' 미국 임상 3상 첫 환자 투약 개시 ↗머니투데이 · Published 2026-07-08 · Sources checked 2026-11-18 · Original unavailable
  3. 메디포스트, 카티스템 일본 임상 3상 성공 ↗한국경제 · Published 2026-05-13 · Sources checked 2026-11-18 · Original unavailable